ATE176237T1 - Sphingoglycolipid und verwendung davon - Google Patents

Sphingoglycolipid und verwendung davon

Info

Publication number
ATE176237T1
ATE176237T1 AT94912682T AT94912682T ATE176237T1 AT E176237 T1 ATE176237 T1 AT E176237T1 AT 94912682 T AT94912682 T AT 94912682T AT 94912682 T AT94912682 T AT 94912682T AT E176237 T1 ATE176237 T1 AT E176237T1
Authority
AT
Austria
Prior art keywords
sphingoglycolipid
represent
relates
monosaccharide unit
specified
Prior art date
Application number
AT94912682T
Other languages
English (en)
Inventor
Tatsuo Higa
Takenori Natori
Yasuhiko Koezuka
Kazuhiro Motoki
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE176237T1 publication Critical patent/ATE176237T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94912682T 1993-04-15 1994-04-14 Sphingoglycolipid und verwendung davon ATE176237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8863093 1993-04-15

Publications (1)

Publication Number Publication Date
ATE176237T1 true ATE176237T1 (de) 1999-02-15

Family

ID=13948136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912682T ATE176237T1 (de) 1993-04-15 1994-04-14 Sphingoglycolipid und verwendung davon

Country Status (11)

Country Link
US (1) US5780441A (de)
EP (1) EP0694558B1 (de)
JP (1) JP4020958B2 (de)
KR (1) KR100281265B1 (de)
CN (1) CN1045302C (de)
AT (1) ATE176237T1 (de)
AU (1) AU683653B2 (de)
CA (1) CA2160566C (de)
DE (1) DE69416306T2 (de)
TW (1) TW295588B (de)
WO (1) WO1994024142A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW261533B (de) * 1992-07-16 1995-11-01 Kirin Brewery
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
WO1998034623A1 (en) * 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
ATE286735T1 (de) * 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
CA2320117A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
JPH11269189A (ja) * 1998-03-19 1999-10-05 Nissin Food Prod Co Ltd 免疫調節作用を有する化合物
JP4099267B2 (ja) * 1998-08-07 2008-06-11 株式会社紀文フードケミファ 乳化剤および乳化組成物
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
EP1551228B1 (de) 2002-06-13 2012-10-03 New York University Synthetisches c-glycolipid und seine verwendung für die behandlung von krebs, infektionskrankheiten und autoimmunerkrankungen
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
AU2005235080A1 (en) * 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
CA2577009C (en) * 2004-08-27 2017-05-02 Steven A. Porcelli Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CA2577125C (en) 2004-10-07 2016-01-12 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5053101B2 (ja) 2005-01-28 2012-10-17 ブリガム ヤング ユニヴァーシティー CD1d−拘束NKT細胞の細菌糖脂質による活性化
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1776963A1 (de) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramiden als Adjuvantien und ihre Verwendung in pharmazeutischen Zusammensetzungen
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
PT2056842E (pt) 2006-04-07 2013-01-24 Univ Chicago Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
US7794722B2 (en) * 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (de) * 2007-11-07 2009-05-13 Wittycell NKT-Zellen aktivierende, kovalent gebundene Glykolipid-Antigene und/oder Arzneimittel
EP2060252A1 (de) 2007-11-19 2009-05-20 Wittycell Neue Formulierung von Galactosylceramid-Derivaten
BRPI0820960B8 (pt) * 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
CA2739765A1 (en) * 2008-10-08 2010-04-15 Vincent Serra Vaccine composition for use against influenza
AU2010203451B2 (en) * 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
WO2010083728A1 (en) 2009-01-23 2010-07-29 Dapeng Zhou Nanoparticle formulated glycolipid antigens for immunotherapy
EP2647384B1 (de) 2010-12-02 2018-05-23 Riken IMMUNTHERAPIE MIT ALLO-NKT-ZELLEN, ZELLEN FÜR DIE IMMUNTHERAPIE MIT UMGEORDNETER aplha KETTE DES T-ZELL REZEPTOR (TCR)-GENS IN GLEICHMÄSSIGE V alpha-J alpha-ANORDNUNG UND LAGERUNG VON NKT-ZELLEN AUS DIESEN ZELLEN
SG11201501289TA (en) 2012-08-22 2015-04-29 Regimmune Corp Preparation for preventing or treating type i diabetes
JP6361004B2 (ja) 2012-11-05 2018-07-25 株式会社レグイミューン 免疫寛容誘導剤
WO2014079946A1 (en) 2012-11-21 2014-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the risk of acute graft versus host disease
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CN106726875B (zh) * 2016-11-24 2019-05-21 晨光生物科技集团股份有限公司 一种含鞘糖脂类物质的提取物的制备方法
JPWO2022118913A1 (de) 2020-12-04 2022-06-09

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4806466A (en) * 1981-10-29 1989-02-21 The Regents Of The University Of California Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
JPS6157594A (ja) * 1984-08-30 1986-03-24 Suntory Ltd ガラクトスフインゴ脂質及びその製造法
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
DD261165A5 (de) * 1985-08-13 1988-10-19 Solco Basel Ag,Ch Neues verfahren zur herstellung von sphingosinderivaten
JPH07116209B2 (ja) * 1986-04-11 1995-12-13 メクト株式会社 シアロシルセラミド類及びその製造方法
US4990603A (en) * 1986-07-04 1991-02-05 Mect Corporation Sialic acid derivatives and process therefor
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
JPS6495A (en) * 1986-12-19 1989-01-05 Tosoh Corp Alpha-glycosyl ceramide derivative
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JP2588729B2 (ja) * 1987-10-05 1997-03-12 塩野義製薬株式会社 スフィンゴシン誘導体
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US5028715A (en) * 1989-02-06 1991-07-02 Southwest Research Institute Radioprotective agents and their method of manufacture
DE69011465T2 (de) * 1989-09-29 1995-03-23 Ajinomoto Kk Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten.
JP3068910B2 (ja) * 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
JPH06145189A (ja) * 1991-01-23 1994-05-24 Kitasato Inst:The スフィンゴ糖脂質
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
TW261533B (de) * 1992-07-16 1995-11-01 Kirin Brewery
US5567684A (en) * 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives

Also Published As

Publication number Publication date
CA2160566A1 (en) 1994-10-27
KR100281265B1 (ko) 2001-02-01
CA2160566C (en) 2004-07-13
DE69416306D1 (de) 1999-03-11
TW295588B (de) 1997-01-11
DE69416306T2 (de) 1999-06-17
CN1124963A (zh) 1996-06-19
CN1045302C (zh) 1999-09-29
WO1994024142A1 (fr) 1994-10-27
AU683653B2 (en) 1997-11-20
EP0694558B1 (de) 1999-01-27
EP0694558A1 (de) 1996-01-31
AU6513094A (en) 1994-11-08
EP0694558A4 (de) 1996-08-21
JP4020958B2 (ja) 2007-12-12
US5780441A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
DE69416306D1 (de) Sphingoglycolipid und verwendung davon
HUT54357A (en) Process for producing benzilidene-(azolylmethyl)-cycloalkane and -cycloalkene derivatives, fungicidal compositions comprising such compounds as active ingredient and intermediates usable for the production of the active ingredients
NO931529L (no) Cykliske fruktopyranosesulfitter og -sulfater med antikonvulsiv effekt
BR8806059A (pt) Composicao de resina termoplastica
SG49084A1 (en) Chemical compounds
ES2149537T3 (es) Resina intercambiadora de aniones no reticulados y composicion farmaceutica que contiene la misma.
ATE109484T1 (de) Thienopyridin -derivative und diese enthaltende arzneimittel.
MY114174A (en) Insecticidal tetrahydrofuran-compound
EP0808825A4 (de) Phenylbenzoesäureester-derivate und flüssigkristallzubereitungen
HUT61773A (en) Process for producing spicamycin derivatives and pharmaceutical compositions containing them as active components
DE69130326D1 (de) Piperidin-verbindungen, ihre darstellung und ihre verwendung
DE69203551D1 (de) Biologisch abbaubarer Copolyester von 4-Hydroxyprolin und diesen enthaltende pharmazeutische Zusammensetzung.
AU641686B2 (en) Benzanilides
EP0601191A4 (en) Novel tetracyclic compound.
GB2271718B (en) Antimicrobial agents comprising polyquaternary ammonium compounds
MY106839A (en) Carboxylate compounds, liquid crystal compositions containing said compounds and liquid crystal elements.
ATE147372T1 (de) Neue quaternäre ammoniumsalze und deren medizinische verwendung
DE69309452D1 (de) Herstellung von aktivierten Carbamaten von Polyalkylenglycol und ihre Verwendung
ES481057A1 (es) Procedimiento para preparar una composicion protectora de - plantas que comprende como antidoto un derivado de 1,4-oxa- za-spirohidrocarburo.
HU9600300D0 (en) Thiocarbamoyl derivatives using as antimicrobial agents and process for producing of these
ATE165094T1 (de) Zytotoxische verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties